<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Clin Exp Hematop</journal-id><journal-id journal-id-type="iso-abbrev">J Clin Exp Hematop</journal-id><journal-id journal-id-type="publisher-id">jslrt</journal-id><journal-title-group><journal-title>Journal of Clinical and Experimental Hematopathology : JCEH</journal-title></journal-title-group><issn pub-type="ppub">1346-4280</issn><issn pub-type="epub">1880-9952</issn><publisher><publisher-name>JSLRT</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31866622</article-id><article-id pub-id-type="pmc">6954171</article-id><article-id pub-id-type="publisher-id">19030</article-id><article-id pub-id-type="doi">10.3960/jslrt.19030</article-id><article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group></article-categories><title-group><article-title>T-cell large granular lymphocytic (LGL) leukemia consists of CD4<sup>+</sup>/CD8<sup>dim</sup> and CD4<sup>-</sup>/CD8<sup>+</sup> LGL populations in association with immune thrombocytopenia, autoimmune neutropenia, and monoclonal B-cell lymphocytosis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kuwahara</surname><given-names>Naoya</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kodaka</surname><given-names>Taiichi</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zushi</surname><given-names>Yuriko</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Sasaki</surname><given-names>Miho</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Goka</surname><given-names>Takae</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Maruoka</surname><given-names>Hayato</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Aoyama</surname><given-names>Yumi</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tsunemine</surname><given-names>Hiroko</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Yamane</surname><given-names>Taku</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kobayashi</surname><given-names>Jun</given-names></name><xref ref-type="aff" rid="aff7"><sup>6</sup></xref><xref ref-type="aff" rid="aff8"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kawakami</surname><given-names>Toru</given-names></name><xref ref-type="aff" rid="aff6"><sup>8</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ishida</surname><given-names>Fumihiro</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref><xref ref-type="aff" rid="aff7"><sup>6</sup></xref><xref ref-type="aff" rid="aff6"><sup>8</sup></xref></contrib><contrib contrib-type="author"><name><surname>Itoh</surname><given-names>Tomoo</given-names></name><xref ref-type="aff" rid="aff9"><sup>9</sup></xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Takahashi</surname><given-names>Takayuki</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff><target id="aff1" target-type="aff"><sup>1)</sup></target>Departments of Hematology, <target id="aff2" target-type="aff"><sup>2)</sup></target>Cell Therapy, and <target id="aff3" target-type="aff"><sup>3)</sup></target>Laboratory Medicine, <institution>Shinko Hospital</institution>, <addr-line>Kobe</addr-line>, <country>Japan</country>, <target id="aff4" target-type="aff"><sup>4)</sup></target>Department of Laboratory Medicine, <institution>Kobe City Medical Center General Hospital</institution>, <addr-line>Kobe</addr-line>, <country>Japan</country>, <target id="aff5" target-type="aff"><sup>5)</sup></target>Departments of Biomedical Laboratory Sciences, <target id="aff6" target-type="aff"><sup>8)</sup></target>Internal Medicine, Division of Hematology, <institution>Shinshu University School of Medicine</institution>, <addr-line>Matsumoto</addr-line>, <country>Japan</country>, <target id="aff7" target-type="aff"><sup>6)</sup></target>Department of Health and Medical Sciences, Graduate School of Medicine, <institution>Shinshu University</institution>, <addr-line>Matsumoto</addr-line>, <country>Japan</country>, <target id="aff8" target-type="aff"><sup>7)</sup></target>Department of Laboratory Medicine, Nagano Children&#x02019;s Hospital, Azumino, <country>Japan</country>, <target id="aff9" target-type="aff"><sup>9)</sup></target>Department of Diagnostic Pathology, <institution>Kobe University Graduate School of Medicine</institution>, <addr-line>Kobe</addr-line>, <country>Japan</country></aff><author-notes><corresp id="cor1">Corresponding author: Takayuki Takahashi, Department of Hematology, Shinko Hospital, 4-47, Wakihama-cho, 1-chome, Chuo-ku, Kobe 651-0072, Japan. E-mail: <email xlink:href="takahashi.takayuki@shinkohp.or.jp">takahashi.takayuki@shinkohp.or.jp</email></corresp></author-notes><pub-date pub-type="epub"><day>22</day><month>12</month><year>2019</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2019</year></pub-date><volume>59</volume><issue>4</issue><fpage>202</fpage><lpage>206</lpage><history><date date-type="received"><day>08</day><month>8</month><year>2019</year></date><date date-type="rev-recd"><day>12</day><month>9</month><year>2019</year></date><date date-type="accepted"><day>08</day><month>10</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; 2019 by The Japanese Society for Lymphoreticular Tissue Research</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>The Japanese Society for Lymphoreticular Tissue
Research</copyright-holder><license specific-use="CC BY-NC-SA 4.0" xlink:href="https://creativecommons.org/licenses/by-nc-sa/4.0/"><license-p>This is an open-access article distributed under the terms of the
Creative Commons Attribution ShareAlike (CC BY-NC-SA) 4.0 License.</license-p></license></permissions><abstract><p>CD3<sup>+</sup>/CD57<sup>+</sup> T-cell large granular lymphocyte leukemia (T-LGLL) is an indolent neoplasm, exhibiting mostly CD8<sup>+</sup>, less frequently CD4<sup>+</sup> phenotypes, and T-LGLL consisting of 2 populations with CD8<sup>+</sup> and CD4<sup>+</sup> phenotypes is markedly rare. An 87-year-old female was admitted under a diagnosis of immune thrombocytopenia (ITP) with a platelet count of 5.0&#x000d7;10<sup>9</sup>/L and increased number of LGL with unknown etiology. Her neutrophil count also decreased to 0.27&#x000d7;10<sup>9</sup>/L and she was positive for antineutrophil antibody. The WBC count was 2.7&#x000d7;10<sup>9</sup>/L with 34.7% LGL and flow cytometry (FCM) analysis revealed 16% CD3<sup>+</sup>/CD4<sup>+</sup>/CD8<sup>dim</sup>/CD57<sup>+</sup> and 20.9% CD3<sup>+</sup>/CD8<sup>+</sup>/CD57<sup>+</sup> populations. These populations also expressed granzyme B and perforin. Circulating mononuclear cells were found to be clonal by PCR analysis of T-cell receptor &#x003b2;-chain gene. Serum immunofixation and bone marrow FCM analyses demonstrated 2 clonal B-cells producing IgG-&#x003bb; and IgA-&#x003bb;. Deep amplicon sequencing of <italic>STAT3</italic> and <italic>STAT5B</italic> genes revealed a <italic>STAT3</italic> R302G mutation with an allele burden of 2.6%. The thrombocytopenia and neutropenia were successfully treated by prednisolone and romiplostim with negative conversion of antineutrophil antibody. This is the first reported case of T-LGLL with dual components of CD4<sup>+</sup>/CD8<sup>dim</sup> and CD4<sup>-</sup>/CD8<sup>+</sup> populations in terms of multiple comorbidities related to the respective CD8<sup>+</sup> and CD4<sup>+</sup> T-LGLLs.</p></abstract><kwd-group kwd-group-type="author"><title>Keywords: &#x02028;</title><kwd>T-cell large granular lymphocytic leukemia</kwd><kwd>CD4</kwd><kwd>CD8</kwd><kwd>immune thrombocytopenia</kwd><kwd>autoimmune neutropenia</kwd><kwd>clonal B-lymphocytosis</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>T-cell large granular lymphocytic leukemia (T-LGLL) is an indolent neoplasm, accounting for 3% of mature lymphoid leukemias.<xref rid="r1" ref-type="bibr"><sup>1</sup></xref><sup>-</sup><xref rid="r3" ref-type="bibr"><sup>3</sup></xref> T-LGLL typically exhibits a CD3<sup>+</sup>, TCRa&#x003b2;<sup>+</sup>, CD4<sup>-</sup>, CD5<sup>dim</sup>, CD8<sup>+</sup>, CD27<sup>-</sup>, CD28<sup>-</sup>, CD45RO<sup>-</sup>, CD45RA<sup>+</sup>, and CD57<sup>+</sup> phenotype.<xref rid="r2" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="r3" ref-type="bibr"><sup>3</sup></xref> CD3<sup>+</sup>/CD56<sup>+</sup> T-LGL leukemia is associated with <italic>STAT5b</italic> mutation and exhibits a more aggressive clinical course than CD3<sup>+</sup>/CD57<sup>+</sup> T-LGLL.<xref rid="r4" ref-type="bibr"><sup>4</sup></xref><sup>,</sup><xref rid="r5" ref-type="bibr"><sup>5</sup></xref> CD3<sup>+</sup>/CD57<sup>+</sup> T-LGLL mostly and rarely exhibits CD8<sup>+</sup> and CD4<sup>+</sup> phenotypes, respectively,<xref rid="r2" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="r6" ref-type="bibr"><sup>6</sup></xref><sup>-</sup><xref rid="r8" ref-type="bibr"><sup>8</sup></xref> and only 3 cases of that consisting of 2 populations with CD8<sup>+</sup> and CD4<sup>+</sup> phenotypes have been described.<xref rid="r9" ref-type="bibr"><sup>9</sup></xref><sup>,</sup><xref rid="r10" ref-type="bibr"><sup>10</sup></xref> CD3<sup>+</sup>/CD8<sup>+</sup>/CD57<sup>+</sup> and CD3<sup>+</sup>/CD4<sup>+</sup>/CD8<sup>dim</sup>/CD57<sup>+</sup> T-LGLLs have characteristic genetic backgrounds of <italic>STAT3</italic><xref rid="r11" ref-type="bibr"><sup>11</sup></xref><sup>,</sup><xref rid="r12" ref-type="bibr"><sup>12</sup></xref> and <italic>STAT5b</italic><xref rid="r10" ref-type="bibr"><sup>10</sup></xref> mutations, respectively. CD3<sup>+</sup>/CD8<sup>+</sup>/CD57<sup>+</sup> T-LGLL is frequently associated with large granular lymphocytosis, autoimmune disease, such as rheumatoid arthritis, autoimmune cytopenia, such as pure red cell aplasia, immune thrombocytopenia (ITP), and autoimmune hemolytic anemia.<xref rid="r12" ref-type="bibr"><sup>12</sup></xref><sup>-</sup><xref rid="r15" ref-type="bibr"><sup>15</sup></xref> However, CD3<sup>+</sup>/CD4<sup>+</sup>/CD8<sup>dim</sup>/CD57<sup>+</sup> T-LGLL is not associated with autoimmune disease/cytopenia, but with B-cell neoplasia such as B-cell chronic lymphocytic leukemia and monoclonal gammopathy with undetermined significance/monoclonal B-cell lymphocytosis.<xref rid="r6" ref-type="bibr"><sup>6</sup></xref><sup>,</sup><xref rid="r16" ref-type="bibr"><sup>16</sup></xref> We report a rare case of T-LGLL consisting of 2 populations with CD3<sup>+</sup>/CD8<sup>+</sup>/CD57<sup>+</sup> and CD3<sup>+</sup>/CD4<sup>+</sup>/ CD8<sup>dim</sup>/CD57<sup>+</sup> phenotypes, being associated with ITP, autoimmune neutropenia, and monoclonal B-cell lymphocytosis. This is the first reported case of T-LGLL with CD4<sup>+</sup>/CD8<sup>+</sup>-dual components and multiple comorbidities related to the respective CD8<sup>+</sup> and CD4<sup>+</sup> T-LGLLs.</p></sec><sec sec-type="materials|methods"><title>MATERIALS AND METHODS</title><p><italic>STAT3</italic> and <italic>STAT5b</italic> gene analyses were performed as previously described<xref rid="r17" ref-type="bibr"><sup>17</sup></xref> using preserved DNA from white blood cells (WBC) after the T-cell receptor (TCR) gene clonal analysis. This study was approved by the ethics committees of Shinko Hospital and Shinshu University School of Medicine, and written informed consent was received from the patient&#x02019;s son.</p></sec><sec sec-type="cases"><title>CASE REPORT</title><p>An 87-year-old female was admitted in November 2016 because of thrombocytopenia of 2.5&#x000d7;10<sup>9</sup>/L, which was revealed to be ITP. At this time, an increased number of LGL (2.4&#x000d7;10<sup>9</sup>/L) and neutropenia (0.29&#x000d7;10<sup>9</sup>/L) were observed with an unknown etiology. As her medical history, she had been diagnosed with rectal cancer, stomach malignant lymphoma (diffuse large B-cell lymphoma: DLBCL), and thyroid cancer at the ages of 74, 75, and 76, respectively. For DLBCL, she received 6 courses of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) followed by 2 courses of rituximab alone at a previous hospital in 2005. The karyotype and immunohistopathological findings regarding the DLBCL were not available. For thyroid cancer, she underwent left lobe resection of the thyroid without following chemotherapy at another hospital in 2006. Chemotherapy was not performed after surgery for the rectal cancer in 2004. ITP was successfully treated by prednisolone (PSL) and romiplostim, and she was discharged. These agents were tapered and discontinued 10 months later.</p><p>In July 2017, she was readmitted because of the recurrence of ITP. Physically, several and many petechiae were observed in the oral cavity and on the bilateral forearms, respectively. Neither superficial lymph node swelling nor hepatosplenomegaly was noted. Laboratory examination demonstrated a WBC count of 2.7&#x000d7;10<sup>9</sup>/L, with 12.9% neutrophils, 0.9% eosinophils, 1.3% basophils, 20.4% monocytes, 29.8% lymphocytes, and 34.7% LGL (<xref ref-type="fig" rid="f1">Figure 1</xref>), a hemoglobin concentration of 11.3 g/dL, and a platelet count of 5.0&#x000d7;10<sup>9</sup>/L. Regarding ITP and neutropenia, platelet-associated IgG was markedly increased to 4,930 ng/10<sup>7</sup> cells (normally below 46 ng/10<sup>7</sup> cells) and anti-neutrophil antibody was positive. Other serological examinations including antinuclear antibody, complements (C3 and C4), rheumatoid factor, and immunoglobulin amounts, were non-specific. Serological tests for Epstein-Barr virus (EBV) revealed a pattern of previous infection, but EBV-DNA was not detected in the blood by multiplex PCR assay. The antibody for human immunodeficiency virus (HIV) was negative. Serological testing for human T-cell leukemia virus type 1 (HTLV-1) was not performed.</p><fig id="f1" fig-type="figure" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Large granular lymphocytes in the peripheral blood in July 2017 (Wright-Giemsa staining, &#x000d7;1,000).</p></caption><graphic xlink:href="jslrt-59-202-g001"/></fig><p>Flow cytometry (FCM) of peripheral blood demonstrated 16% CD3<sup>+</sup>/CD4<sup>+</sup>/CD8<sup>dim</sup>/CD57<sup>+</sup> and 20.9% CD3<sup>+</sup>/CD4<sup>-</sup>/CD8<sup>+</sup>/CD57<sup>+</sup> populations in nucleated cells with a CD4/CD8 ratio of 0.86 (<xref ref-type="fig" rid="f2">Figure 2A</xref>). These cell populations also expressed granzyme B, perforin (<xref ref-type="fig" rid="f2">Figure 2B</xref>), and TCR&#x003b1;&#x003b2; (data not shown). The summation of the percentages of CD3<sup>+</sup>/CD4<sup>+</sup>/CD8<sup>dim</sup>/CD57<sup>+</sup> and CD3<sup>+</sup>/CD4<sup>-</sup>/CD8<sup>+</sup>/CD57<sup>+</sup> populations by FCM was similar to that of the morphologically evaluated LGL (34.7%), suggesting that the LGL consisted of both CD4<sup>+</sup> and CD8<sup>+</sup> populations. CD16 of these mononuclear cells was negative on 2 incidences of FCM on the peripheral blood and bone marrow. Multiplex PCR analysis of WBC demonstrated monoclonal rearrangement of the TCR-&#x003b2; chain gene but not &#x003b3;-chain (data not shown). A monoclonally rearranged band of the TCR- &#x003b2; gene was also observed on PCR analysis of bone marrow cells (data not shown).</p><fig id="f2" fig-type="figure" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>Flow cytometric analysis of peripheral blood performed using strong CD45 gating. The value in each area in respective cytograms indicates % of cells among CD45-strongly positive mononuclear cells. Based on these data, the % of CD3<sup>+</sup>/CD4<sup>+</sup>/CD8<sup>dim</sup>/CD57<sup>+</sup> and CD3<sup>+</sup>/CD4<sup>-</sup>/CD8<sup>+</sup>/CD57<sup>+</sup> populations in WBC (nucleated cells) were 16.0% and 20.9%, respectively (<xref ref-type="fig" rid="f2">Figure 2<italic>A</italic></xref>). These CD4<sup>+</sup> and CD8<sup>+</sup> cell populations also expressed granzyme B and perforin (<xref ref-type="fig" rid="f2">Figure 2<italic>B</italic></xref>).</p></caption><graphic xlink:href="jslrt-59-202-g002"/></fig><p>An M-peak was observed on serum electrophoresis (<xref ref-type="fig" rid="f3">Figure 3A</xref>), and immunofixation revealed monoclonal bands of IgG-&#x003bb; and faint IgA with an unknown light chain (<xref ref-type="fig" rid="f3">Figure 3B</xref>). On FCM analysis of bone marrow cells, a B-cell population with a CD19<sup>+</sup>/CD38<sup>+</sup>/sm&#x003bb;<sup>+</sup>/sm&#x003ba;<sup>&#x02212;</sup> phenotype comprised 3.8% of marrow nucleated cells (<xref ref-type="fig" rid="f4">Figure 4</xref>). Of CD19<sup>+</sup> cells, cy&#x003b1;<sup>+</sup>/cy&#x003bb;<sup>+</sup>, cy&#x003bb;<sup>+</sup>, and cy&#x003ba;<sup>-</sup> cells comprised 1.2, 5.9, and 0.3% of marrow cells, respectively (<xref ref-type="fig" rid="f4">Figure 4</xref>). Considering the results of serum immunofixation and marrow FCM analyses, there were 2 clonal B-cells producing IgG-&#x003bb; and IgA-&#x003bb; in the bone marrow. The bone marrow picture was non-specific except for LGL and lymphoplasmacytic cells (<xref ref-type="fig" rid="f5">Figure 5</xref>), which comprised 5.0 and 5.6% of nucleated cells, respectively. We did not prepare marrow biopsy or clot preparations. Chromosomal examination of the marrow cells revealed an abnormal karyotype of 46,XX, ?t(3;9)(q27;q22) in 5 of the 20 dividing cells analyzed.</p><fig id="f3" fig-type="figure" orientation="portrait" position="float"><label>Fig. 3</label><caption><p>An M-peak was observed on serum electrophoresis (arrow) (<xref ref-type="fig" rid="f3">Figure 3<italic>A</italic></xref>), and immunofixation showed monoclonal bands of IgG-&#x003bb; and faint IgA with an unknown light chain (arrows) (<xref ref-type="fig" rid="f3">Figure 3<italic>B</italic></xref>).</p></caption><graphic xlink:href="jslrt-59-202-g003"/></fig><fig id="f4" fig-type="figure" orientation="portrait" position="float"><label>Fig. 4</label><caption><p>Flow cytometric analysis of bone marrow cells with strong CD45 gating. The value in each area in respective cytograms indicates the % of cells among CD45-strongly positive mononuclear cells. The analysis subsequently revealed a population with a CD19<sup>+</sup>/sm&#x003bb;<sup>+</sup>/sm&#x003ba;<sup>&#x02212;</sup> phenotype comprising 3.8% of marrow nucleated cells. Cytoplasmic immunoglobulin analysis showed that cy&#x003b1;<sup>+</sup>/cy&#x003bb;<sup>+</sup>, cy&#x003bb;<sup>+</sup>, and cy&#x003ba;<sup>-</sup> cells comprised 1.2, 5.9, and 0.3% of marrow nucleated cells, respectively. Surface and cytoplasmic IgG were not detected, possibly due to unknown problems associated with the use of monoclonal anti-IgG antibody in this analysis.</p></caption><graphic xlink:href="jslrt-59-202-g004"/></fig><fig id="f5" fig-type="figure" orientation="portrait" position="float"><label>Fig. 5</label><caption><p>Lymphoplasmacytic cells in the bone marrow comprised 5.6% of marrow nucleated cells (Wright-Giemsa staining, &#x000d7;1,000).</p></caption><graphic xlink:href="jslrt-59-202-g005"/></fig><p>Based on these results, a final diagnosis of 2-population T-LGLL with CD4<sup>+</sup> and CD8<sup>+</sup> phenotypes, associated with ITP, autoimmune neutropenia, and clonal B-cell lymphocytosis consisting of 2 populations producing IgG-&#x003bb; and IgA-&#x003bb;, was made. ITP was successfully treated with PSL and romiplostim, with subsequent improvement of neutropenia and negative conversion of antineutrophil antibody, and the patient was discharged in August 2017. The T-LGLL was stable with platelet counts of around 55&#x000d7;10<sup>9</sup>/L. However, in November 2017, the patient died of DLBCL in the abdominal cavity, which may have been transformed from the above-mentioned marrow clonal B-cells because the pathological diagnosis of this lymphoma was DLBCL (CD20<sup>+</sup>/<italic>Bcl-2</italic><sup>+</sup>/CD5<sup>-</sup>/CD10<sup>-</sup>/<italic>c-myc</italic><sup>-</sup>/EBER<sup>-</sup>) with plasmacytic differentiation, and FCM analysis confirmed 2 populations of abnormal B-cells with phenotypes of CD19<sup>+</sup>/CD20<sup>+</sup>/sm&#x000b7;cy&#x003ba;<sup>+</sup>/cyIgM<sup>dim</sup>/CD5<sup>-</sup>/CD10<sup>-</sup>/smIg (A, D, M, G)<sup>-</sup>/cyIg (A, D, G)<sup>-</sup>/sm&#x000b7;cy&#x003bb;<sup>-</sup> (33.4% of mononuclear cells) and CD45<sup>dim</sup>/CD19<sup>din</sup>/CD10<sup>+</sup>/cyIgA<sup>+</sup>/CD5<sup>-</sup>/CD20<sup>-</sup>/smIg (A, D, M, G)<sup>-</sup>/cyIg (M, D, G)<sup>-</sup>/sm&#x000b7;cy&#x003ba; and &#x003bb;<sup>-</sup> (6.0%). Chromosomal and fluorescence in situ hybridization (FISH) analyses were not performed on this lymphoma specimen.</p><p>Mutation analyses of <italic>STAT3</italic> and <italic>STAT5</italic> genes revealed a <italic>STAT3</italic> R302G mutation with an allele burden of 2.6%.</p></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>In the present patient, an unusual lymphocyte population with a CD3<sup>+</sup>/CD4<sup>+</sup>/CD8<sup>dim</sup>/CD57<sup>+</sup> phenotype as T-LGLL was observed. The CD4<sup>+</sup> population, however, expressed CD57, granzyme B, and perforin, similar to the CD8<sup>+</sup> population. Although we did not perform clonal analyses, such as PCR or Southern blotting, on isolated CD4 and CD8 populations as Richards <italic>et al</italic>. did,<xref rid="r9" ref-type="bibr"><sup>9</sup></xref> the expression of CD57 and cytotoxic molecules in these 2 T-cell populations supports that these 2 populations originated from the same clone. Therefore, this case was diagnosed as extremely rare 2-population T-LGLL with CD4<sup>+</sup> and CD8<sup>+</sup> phenotypes. Only 3 cases of this dual-population T-LGLL have been reported. However, comorbidities related to the respective CD8<sup>+</sup> and CD4<sup>+</sup> T-LGLL were not described.<xref rid="r9" ref-type="bibr"><sup>9</sup></xref><sup>,</sup><xref rid="r10" ref-type="bibr"><sup>10</sup></xref></p><p>In normal T-cell differentiation from double-positive T-cells to single-positive cells, mutually exclusive transcription factors, <italic>ThPOK</italic> and <italic>Runx3</italic>, induce CD4<sup>+</sup>- and CD8<sup>+</sup> single-positive cells, respectively.<xref rid="r18" ref-type="bibr"><sup>18</sup></xref> On the other hand, in a T-cell neoplasm, differentiation from double-positive T-cells to single-positive T-cells occurs with restriction of CD4<sup>+</sup>- or CD8<sup>+</sup> single-positive cells. In this situation, it is hypothesized that only one of the 2 transcription factors acts due to tumor-altered gene regulation. In the present case, both <italic>ThPOK</italic> and Runx3 may have abnormally functioned at the stage of neoplastic double-positive T-cells, resulting in the generation of both CD3<sup>+</sup>/CD4<sup>+</sup>/CD8<sup>dim</sup>/CD57<sup>+</sup> and CD3<sup>+</sup>/CD4<sup>-</sup>/CD8<sup>+</sup>/CD57<sup>+</sup> populations. Of note, the former population also expressed cytotoxic molecules, granzyme B and perforin. <italic>ThPOK</italic> negatively regulates the expression of <italic>Runx3</italic> and CD8 lineage genes, resulting in the suppression of CD8, granzyme B, and perforin expression.<xref rid="r19" ref-type="bibr"><sup>19</sup></xref><sup>,</sup><xref rid="r20" ref-type="bibr"><sup>20</sup></xref>
<italic>ThPOK</italic> in this patient, therefore, may have incompletely suppressed CD8 lineage molecules.</p><p>The CD4<sup>+</sup>/CD8<sup>+</sup>-dual populations demonstrated notable clinical pictures in this patient: 2 autoimmune phenomena of ITP and autoimmune neutropenia, which are frequently associated with CD8<sup>+</sup> T-LGLL,<xref rid="r12" ref-type="bibr"><sup>12</sup></xref><sup>-</sup><xref rid="r15" ref-type="bibr"><sup>15</sup></xref> and clonal B-cell lymphocytosis consisting of 2 B-cell populations, which is associated with CD4<sup>+</sup> T-LGLL.<xref rid="r6" ref-type="bibr"><sup>6</sup></xref><sup>,</sup><xref rid="r16" ref-type="bibr"><sup>16</sup></xref> The clinical picture of the present patient, therefore, is of interest and novel in terms of rare CD4<sup>+</sup>/CD8<sup>+</sup>-dual component T-LGL leukemia and multifarious comorbidities related to the respective CD8<sup>+</sup> and CD4<sup>+</sup> T-LGLLs.</p><p>The intra-abdominal DLBCL that developed in November 2017 may have originated from monoclonal marrow B cells because of plasmacytic differentiation of the DLBCL on pathological examination and the presence of cyIgA-positive abnormal B-cells, as previously detected in the bone marrow by FCM analyses. The abnormal karyotype of 46,XX, ?t(3;9)(q27;q22) observed in the bone marrow may also support this possibility because 3q27 involves <italic>Bcl-6</italic>, and abnormality of this gene is observed in many DLBCL. The relationship of stomach DLBCL at the age of 75 with the late-appearing DLBCL is unclear in this patient because immunohistochemical and chromosomal information of the stomach DLBCL were not available.</p><p>Mutation analyses of <italic>STAT3</italic> and <italic>STAT5</italic> genes revealed a <italic>STAT3</italic> R302G mutation. R302G mutation has not been reported in T-LGLL; however, R302W mutation was described in adenoma of the adrenal cortex in the Catalogue of Somatic Mutations in Cancer (COSMIC v88, March 2019), and classified as pathogenic. <italic>STAT3</italic> mutations are common in T-LGLL and considered to be useful for appropriately managing patients.<xref rid="r2" ref-type="bibr"><sup>2</sup></xref></p><p>In conclusion, we report the first case of T-LGLL with CD4<sup>+</sup>/CD8<sup>+</sup>-dual components and multiple comorbidities related to the respective CD8<sup>+</sup> and CD4<sup>+</sup> T-LGLLs with <italic>STAT3</italic> R302G mutation.</p></sec></body><back><ack><title>ACKNOWLEDGMENTS</title><p>The authors are grateful to Miss Mizue Higashi for her excellent support for manuscript preparation and literature search.</p></ack><fn-group><fn fn-type="COI-statement"><p><bold>CONFLICT OF INTEREST:</bold> The authors declare no conflict of interest regarding this study.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Semenzato</surname><given-names>G</given-names></name><name><surname>Zambello</surname><given-names>R</given-names></name><name><surname>Starkebaum</surname><given-names>G</given-names></name><name><surname>Oshimi</surname><given-names>K</given-names></name><name><surname>Loughran</surname><given-names>TP</given-names><suffix>Jr</suffix></name></person-group>
<article-title>The lymphoproliferative disease of granular lymphocytes: updated criteria for diagnosis.</article-title>
<source>Blood</source>. <year>1997</year>; <volume>89</volume>: <fpage>256</fpage>-<lpage>260</lpage>.<pub-id pub-id-type="pmid">8978299</pub-id></mixed-citation></ref><ref id="r2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamy</surname><given-names>T</given-names></name><name><surname>Moignet</surname><given-names>A</given-names></name><name><surname>Loughran</surname><given-names>TP</given-names><suffix>Jr</suffix></name></person-group>
<article-title>LGL leukemia: from pathogenesis to treatment.</article-title>
<source>Blood</source>. <year>2017</year>; <volume>129</volume>: <fpage>1082</fpage>-<lpage>1094</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2016-08-692590</pub-id><pub-id pub-id-type="pmid">28115367</pub-id></mixed-citation></ref><ref id="r3"><label>3</label><mixed-citation publication-type="book">Chan WC, Foucar K, Morice WG, Matutes E. T-cell large granular lymphocytic leukaemia. In: Swerdlow SH, Campo E, Harris NL, <italic>et al</italic>. (eds): WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed, Lyon, IARC, World Health Organization. 2017; pp. 348-350.</mixed-citation></ref><ref id="r4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gentile</surname><given-names>TC</given-names></name><name><surname>Uner</surname><given-names>AH</given-names></name><name><surname>Hutchison</surname><given-names>RE</given-names></name><etal/></person-group>
<article-title>CD3+, CD56+ aggressive variant of large granular lymphocyte leukemia [see comments].</article-title>
<source>Blood</source>. <year>1994</year>; <volume>84</volume>: <fpage>2315</fpage>-<lpage>2321</lpage>. <pub-id pub-id-type="doi">10.1182/blood.V84.7.2315.2315</pub-id><pub-id pub-id-type="pmid">7522625</pub-id></mixed-citation></ref><ref id="r5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajala</surname><given-names>HLM</given-names></name><name><surname>Eldfors</surname><given-names>S</given-names></name><name><surname>Kuusanm&#x000e4;ki</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Discovery of somatic <italic>STAT5b</italic> mutations in large granular lymphocytic leukemia.</article-title>
<source>Blood</source>. <year>2013</year>; <volume>121</volume>: <fpage>4541</fpage>-<lpage>4550</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2012-12-474577</pub-id><pub-id pub-id-type="pmid">23596048</pub-id></mixed-citation></ref><ref id="r6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matos</surname><given-names>DM</given-names></name><name><surname>de Oliveira</surname><given-names>ACV</given-names></name><name><surname>de Nazar&#x000e9; Amaral Tom&#x000e9;</surname><given-names>M</given-names></name><name><surname>Scrideli</surname><given-names>CA</given-names></name></person-group>
<article-title>Monoclonal B-cell lymphocytosis (MBL), CD4+/CD8weak T-cell large granular lymphocytic leukemia (T-LGL leukemia) and monoclonal gammopathy of unknown significance (MGUS): molecular and flow cytometry characterization of three concomitant hematological disorders.</article-title>
<source>Med Oncol</source>. <year>2012</year>; <volume>29</volume>: <fpage>3557</fpage>-<lpage>3560</lpage>. <pub-id pub-id-type="doi">10.1007/s12032-012-0271-3</pub-id><pub-id pub-id-type="pmid">22688448</pub-id></mixed-citation></ref><ref id="r7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Park</surname><given-names>CJ</given-names></name><name><surname>Jang</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>A case of CD4(<sup>+</sup>)T-cell large granular lymphocytic leukemia.</article-title>
<source>Ann Lab Med</source>. <year>2013</year>; <volume>33</volume>: <fpage>196</fpage>-<lpage>199</lpage>. <pub-id pub-id-type="doi">10.3343/alm.2013.33.3.196</pub-id><pub-id pub-id-type="pmid">23667847</pub-id></mixed-citation></ref><ref id="r8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Covach</surname><given-names>A</given-names></name><name><surname>Leith</surname><given-names>CP</given-names></name><name><surname>Rajguru</surname><given-names>SA</given-names></name><name><surname>Yang</surname><given-names>DT</given-names></name></person-group>
<article-title>A unique CD4<sup>+</sup> large granular lymphocytosis occurring in patients treated with tumor necrosis factor &#x003b1; inhibitors: report of 2 cases.</article-title>
<source>Hum Pathol</source>. <year>2015</year>; <volume>46</volume>: <fpage>1237</fpage>-<lpage>1241</lpage>. <pub-id pub-id-type="doi">10.1016/j.humpath.2015.04.015</pub-id><pub-id pub-id-type="pmid">26022501</pub-id></mixed-citation></ref><ref id="r9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richards</surname><given-names>SJ</given-names></name><name><surname>Short</surname><given-names>M</given-names></name><name><surname>Steed</surname><given-names>AJ</given-names></name><name><surname>Scott</surname><given-names>CS</given-names></name></person-group>
<article-title>A biclonal large granular lymphocyte (LGL)/NK-associated (NKa) disorder of CD4 <sup>+</sup> and CD8 <sup>+</sup> lymphocyte subpopulations characterized by the simultaneous presence of distinct TCR rearrangements.</article-title>
<source>Br J Haematol</source>. <year>1994</year>; <volume>88</volume>: <fpage>629</fpage>-<lpage>632</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2141.1994.tb05087.x</pub-id><pub-id pub-id-type="pmid">7819080</pub-id></mixed-citation></ref><ref id="r10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersson</surname><given-names>EI</given-names></name><name><surname>Tanahashi</surname><given-names>T</given-names></name><name><surname>Sekiguchi</surname><given-names>N</given-names></name><etal/></person-group>
<article-title>High incidence of activating <italic>STAT5B</italic> mutations in CD4-positive T-cell large granular lymphocyte leukemia.</article-title>
<source>Blood</source>. <year>2016</year>; <volume>128</volume>: <fpage>2465</fpage>-<lpage>2468</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2016-06-724856</pub-id><pub-id pub-id-type="pmid">27697773</pub-id></mixed-citation></ref><ref id="r11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koskela</surname><given-names>HLM</given-names></name><name><surname>Eldfors</surname><given-names>S</given-names></name><name><surname>Ellonen</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>Somatic <italic>STAT3</italic> mutations in large granular lymphocytic leukemia.</article-title>
<source>N Engl J Med</source>. <year>2012</year>; <volume>366</volume>: <fpage>1905</fpage>-<lpage>1913</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1114885</pub-id><pub-id pub-id-type="pmid">22591296</pub-id></mixed-citation></ref><ref id="r12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jerez</surname><given-names>A</given-names></name><name><surname>Clemente</surname><given-names>MJ</given-names></name><name><surname>Makishima</surname><given-names>H</given-names></name><etal/></person-group>
<article-title><italic>STAT3</italic> mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia.</article-title>
<source>Blood</source>. <year>2012</year>; <volume>120</volume>: <fpage>3048</fpage>-<lpage>3057</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2012-06-435297</pub-id><pub-id pub-id-type="pmid">22859607</pub-id></mixed-citation></ref><ref id="r13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Go</surname><given-names>RS</given-names></name><name><surname>Li</surname><given-names>CY</given-names></name><name><surname>Tefferi</surname><given-names>A</given-names></name><name><surname>Phyliky</surname><given-names>RL</given-names></name></person-group>
<article-title>Acquired pure red cell aplasia associated with lymphoproliferative disease of granular T lymphocytes.</article-title>
<source>Blood</source>. <year>2001</year>; <volume>98</volume>: <fpage>483</fpage>-<lpage>485</lpage>. <pub-id pub-id-type="doi">10.1182/blood.V98.2.483</pub-id><pub-id pub-id-type="pmid">11435321</pub-id></mixed-citation></ref><ref id="r14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiu</surname><given-names>ZY</given-names></name><name><surname>Fan</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><etal/></person-group>
<article-title><italic>STAT3</italic> mutations are frequent in T-cell large granular lymphocytic leukemia with pure red cell aplasia.</article-title>
<source>J Hematol Oncol</source>. <year>2013</year>; <volume>6</volume>: <fpage>82</fpage>. <pub-id pub-id-type="doi">10.1186/1756-8722-6-82</pub-id><pub-id pub-id-type="pmid">24283217</pub-id></mixed-citation></ref><ref id="r15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishida</surname><given-names>F</given-names></name><name><surname>Matsuda</surname><given-names>K</given-names></name><name><surname>Sekiguchi</surname><given-names>N</given-names></name><etal/></person-group>
<article-title><italic>STAT3</italic> gene mutations and their association with pure red cell aplasia in large granular lymphocyte leukemia.</article-title>
<source>Cancer Sci</source>. <year>2014</year>; <volume>105</volume>: <fpage>342</fpage>-<lpage>346</lpage>. <pub-id pub-id-type="doi">10.1111/cas.12341</pub-id><pub-id pub-id-type="pmid">24350896</pub-id></mixed-citation></ref><ref id="r16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lima</surname><given-names>M</given-names></name><name><surname>Almeida</surname><given-names>J</given-names></name><name><surname>Dos Anjos Teixeira</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>TCRalphabeta+/CD4+ large granular lymphocytosis: a new clonal T-cell lymphoproliferative disorder.</article-title>
<source>Am J Pathol</source>. <year>2003</year>; <volume>163</volume>: <fpage>763</fpage>-<lpage>771</lpage>. <pub-id pub-id-type="doi">10.1016/S0002-9440(10)63703-0</pub-id><pub-id pub-id-type="pmid">12875995</pub-id></mixed-citation></ref><ref id="r17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawakami</surname><given-names>T</given-names></name><name><surname>Sekiguchi</surname><given-names>N</given-names></name><name><surname>Kobayashi</surname><given-names>J</given-names></name><etal/></person-group>
<article-title><italic>STAT3</italic> mutations in natural killer cells are associated with cytopenia in patients with chronic lymphoproliferative disorder of natural killer cells.</article-title>
<source>Int J Hematol</source>. <year>2019</year>; <volume>109</volume>: <fpage>563</fpage>-<lpage>571</lpage>. <pub-id pub-id-type="doi">10.1007/s12185-019-02625-x</pub-id><pub-id pub-id-type="pmid">30859397</pub-id></mixed-citation></ref><ref id="r18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Overgaard</surname><given-names>NH</given-names></name><name><surname>Jung</surname><given-names>JW</given-names></name><name><surname>Steptoe</surname><given-names>RJ</given-names></name><name><surname>Wells</surname><given-names>JW</given-names></name></person-group>
<article-title>CD4 <sup>+</sup> /CD8 <sup>+</sup> double-positive T cells: more than just a developmental stage?</article-title>
<source>J Leukoc Biol</source>. <year>2015</year>; <volume>97</volume>: <fpage>31</fpage>-<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1189/jlb.1RU0814-382</pub-id><pub-id pub-id-type="pmid">25360000</pub-id></mixed-citation></ref><ref id="r19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Wildt</surname><given-names>KF</given-names></name><name><surname>Castro</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>The zinc finger transcription factor Zbtb7b represses CD8-lineage gene expression in peripheral CD4+ T cells.</article-title>
<source>Immunity</source>. <year>2008</year>; <volume>29</volume>: <fpage>876</fpage>-<lpage>887</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2008.09.019</pub-id><pub-id pub-id-type="pmid">19062319</pub-id></mixed-citation></ref><ref id="r20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Egawa</surname><given-names>T</given-names></name><name><surname>Littman</surname><given-names>DR</given-names></name></person-group>
<article-title>ThPOK acts late in specification of the helper T cell lineage and suppresses Runx-mediated commitment to the cytotoxic T cell lineage.</article-title>
<source>Nat Immunol</source>. <year>2008</year>; <volume>9</volume>: <fpage>1131</fpage>-<lpage>1139</lpage>. <pub-id pub-id-type="doi">10.1038/ni.1652</pub-id><pub-id pub-id-type="pmid">18776905</pub-id></mixed-citation></ref></ref-list></back></article>